Novartis has not decided what to do with its Sandoz generics unit after announcing a strategic review of the business last year, its chief executive said on Monday.. | January 10, 2022
Swiss drugmaker Novartis AG is
buying Gyroscope Therapeutics for up to $1.5 billion, looking to
bolster its gene therapy roster with the British firm s
treatment for geographic atrophy, a leading. | December 22, 2021
By Cristina Roca Novartis AG said Thursday that it will use the proceeds from the recent sale of its stake in Roche Holding AG to buy back up to $15 billion of its shares by the end of. | December 16, 2021
Novartis AG is launching
a new share buyback worth up to $15 billion to be executed by
the end of 2023, it said on Thursday, adding it was confident in
its top-line growth and deep pipeline. . | December 16, 2021
Novartis s potential sale of its Sandoz generic drug business is attracting interest from possible buyers, Chief Executive Vas Narasimhan said in an interview to be published on Friday.. | December 10, 2021